News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jul 18, 2022
View video here: https://youtu.be/KCT2wzOqmNo CAMBRIDGE, Mass., July 18, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe...
-
Jun 30, 2022
Biomarkers show the potential of NeuroSense's combination drug CogniC to treat Alzheimer's disease CogniC is expected to advance into clinical trials in 2023 CAMBRIDGE, Mass., June 30, 2022...
-
Jun 27, 2022
Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline...
-
Jun 22, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group's...
-
Jun 1, 2022
Phase IIa study successfully met safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biomarkers PrimeC...